Rudolph Tanzi, PhD, of the Harvard Medical School describes a fundamental problem with modern-day treatment of Alzheimer's disease. Series: "Wellbeing " [Health and Medicine] [Show ID: 34243]
Dale Bredesen, MD, UCSF and UCLA, discusses how environmental toxins may lead to Alzheimers disease. Series: "UCSF Consortium for Obesity Assessment, Study and Treatment" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34090]
There are different types of genetic influences on people's risk of developing Alzheimer's disease. Douglas Galasko, MD, of the UCSD Shiley-Marcos Alzheimer’s Disease Research Center joins William Mobley, MD, PhD to discuss these genes, how they are being studied, and what being a carrier of Alzheimer's associated genes means. Learn more about penetrance and expressivity, genome-wide association studies, and more. Series: "Brain Channel" [Health and Medicine] [Show ID: 33725]
How do you model a disease process that stretches out over 20 years in a way that helps you intervene in that process? In the inaugural Shiley Endowed Lecture, Bradley Hyman, MD, PhD shares his research on the progression of Alzheimer's disease. Series: "Brain Channel" [Health and Medicine] [Science] [Show ID: 33992]
Jennifer A. Dresen, MSW, MPH. Chief of Health and Housing Services, The Arc San Francisco Series: "Developmental Disabilities Update" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 33522]
Michael Rafii, MD, PhD describes the conditions that affect people with Down syndrome including vision issues, hearing issues, hormonal issue, spinal cord issues, sleep apnea, and Alzheimer's disease. He stresses the need for routine medical follow ups with primary care physicians and specialty clinics to make sure all changes in health are addressed. Series: "Brain Channel" [Health and Medicine] [Science] [Show ID: 33603]
Karen Gaffney, advocate and disability champion, discusses her life with Down syndrome. She also talks about the impact that pre natal testing is having on the Down syndrome community and advocates for medical research to focus on the immediate needs such as Alzheimer's disease prevention. Series: "Brain Channel" [Health and Medicine] [Science] [Show ID: 33602]
William Mobley, MD, PhD shares the latest research on preventing Alzheimer's disease in people with Down syndrome. He looks at the genetics and progression of both conditions and shares potential therapies to reduce APP expression that leads to dementia. Series: "Alzheimer’s Disease" [Health and Medicine] [Science] [Show ID: 33600]
Can (Martin) Zhang of Harvard Medical School leads off the panel with a detailed discussion of factors leading to Alzheimer’s disease and the potential benefits of curcumin in treatment. He is followed by Rinchen Dhondrup of Qinghai University, who presents on treating chronic atrophic gastritis and Chenchen Wang of Tufts University who explains her work using Tibetan medicines and Tai Chi to treat rheumatoid arthritis, fibromyalgia and other chronic diseases as part of the Tibetan Medicine Conf...
Keynote talks at the 2017 Tibetan Medicine Conference on Mind-Body Health are presented here, including Rudolph Tanzi, PhD, of the Harvard Medical School who describes his research with natural products to prevent and treat Alzheimer's; Yumba of Lhasa on the Great Treasury of Tibetan Medical and Astronomical Texts; and Janet Gyatso of the Harvard Divinity School on the Challenges for the Study of Tibetan Medicine. Series: "Wellbeing " [Health and Medicine] [Show ID: 33044]
Can we turn off the genes responsible for neurodegenerative diseases? Designer DNA drugs are making this possible. By identifying and targeting the genes that drive disease, scientists are moving closer to treatments for ALS, Huntington's disease, and more. Don W. Cleveland, PhD, Department of Cellular and Molecular Medicine, UC San Diego joins William Mobley, MD, PhD to talk about how these drugs work and how they will impact patient care. Series: "Brain Channel" [Health and Medicine] [Science]...
Igor Grant, MD, FRCP(C) pursues research that addresses real world behavioral problems. Studying the intersection of drugs of abuse (primarily methamphetamine) and infection, his work sheds light on the basic mechanisms of injury for people with HIV. He examines inflammation in the context of neurological disorders and measures the impact of chronic stress on Alzheimer's disease caregivers. Dr. Grant joins William Mobley, MD, PhD to discuss his life in science and his fascinating work. Series: "...
2016 Kavli Prize recipient Carla Shatz from Stanford University presents a lively exploration of how understanding early stages of neural development may be leading to a pathway for developing treatments for Alzheimer's Disease. Series: "Alzheimer’s Disease" [Health and Medicine] [Science] [Show ID: 31763]
Eric Siemers, MD, Distinguished Medical Fellow at Eli Lilly and Company joins William Mobley, MD, PhD to discuss clinical trails for Alzheimer's disease. He explains the trial design, results, and future implications of the EXPEDITION3 trial for people with with mild dementia due to Alzheimer's disease. Learn more about potential treatments in the clinical trials pipeline that may impact both the symptoms and pathologies of Alzheimer's disease. Series: "Alzheimer’s Disease" [Health and Medicine]...
As baby boomers age, an unprecedented number of people will be diagnosed with Alzheimer's disease. The economic and social impacts will be wide reaching from cost of treatment to the effect on caregivers. Maria Carrillo, PhD, Chief Science Officer, Alzheimer’s Association joins Willliam Mobley. MD, PhD to discuss what can be done and how government, industry and the Alzheimer's Association are working together on larger scale trials and innovative projects. Series: "Alzheimer’s Disease" [Health ...
Ara Khachaturian, PhD, chair and president of the National Biomedical Research Ethics Council joins WIilliam Mobley, MD, PhD to discuss the evolution of biomedical research in Alzheimer's disease and the ethical standards needed to maintain excellent patient care. From institutional review boards (IRB) to industry and academic partnerships, learn how we can support and maintain effective research infrastructure. Series: "Alzheimer’s Disease" [Health and Medicine] [Show ID: 31770]
Phyllis Ferrell, Vice President and Global Development Leader for Alzheimer's Disease at Eli Lilly and Company joins William Mobley, MD, PhD to talk about the goal set forth in the National Plan to Address Alzheimer’s Disease to “prevent and effectively treat Alzheimer’s disease by 2025.” Ferrell's shares her work to make Alzheimer's dementia preventable by finding ways to slow disease progression and advocating for early diagnosis. Series: "Alzheimer’s Disease" [Health and Medicine] [Show ID: 3...
From neuropathology to molecular target to clinical treatments, where are we on the road to finding an effective treatment for Alzheimer's disease? Howard Feldman, MD, FRCP(C), a neurologist noted for his original research in geriatric cognitive disorders and expertise in large-scale clinical trials, walks through the latest research and shares some tips on brain health. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Science] [Show ID: 31035]
For the past three decades the largest family in the world with a genetic form of Alzheimer’s disease has been tracked. This extended family of some 5,000 individuals live in Antioquia, Colombia among a people who call themselves Paisa. Passing relentlessly through the generations with 100% penetrance is a mutation that causes early onset Alzheimer’s disease in its carriers. Dr. Kenneth Kosik explains that the mutation in the Americas likely originated from a Spanish conquistador whose progeny a...
What is the relationship between sleep, brain health, and Alzheimer's disease? Series: "Wellbeing " [Health and Medicine] [Show ID: 31286]
